Latest Insider Transactions at Intellia Therapeutics, Inc. (NTLA)
This section provides a real-time view of insider transactions for Intellia Therapeutics, Inc. (NTLA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Intellia Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Intellia Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 22
2024
|
Edward J Dulac Iii EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
66,324
+50.0%
|
-
|
|
Jul 01
2024
|
Michael P Dube VP, PAO and Interim PFO |
BUY
Grant, award, or other acquisition
|
Direct |
17,801
+26.64%
|
-
|
|
Jul 01
2024
|
Eliana Clark EVP, Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
405
-0.56%
|
$8,910
$22.93 P/Share
|
|
Jun 17
2024
|
Frank Verwiel |
SELL
Open market or private sale
|
Direct |
1,505
-7.74%
|
$37,625
$25.0 P/Share
|
|
Jun 13
2024
|
Brian Goff |
BUY
Grant, award, or other acquisition
|
Direct |
15,409
+50.0%
|
-
|
|
Jun 12
2024
|
Jesse Goodman |
BUY
Grant, award, or other acquisition
|
Direct |
7,737
+28.46%
|
-
|
|
Jun 12
2024
|
Georgia Keresty |
BUY
Grant, award, or other acquisition
|
Direct |
7,737
+24.47%
|
-
|
|
Jun 12
2024
|
Frank Verwiel |
BUY
Grant, award, or other acquisition
|
Direct |
7,737
+28.46%
|
-
|
|
Jun 12
2024
|
William J Chase |
BUY
Grant, award, or other acquisition
|
Direct |
7,737
+22.47%
|
-
|
|
Jun 12
2024
|
Muna Bhanji |
BUY
Grant, award, or other acquisition
|
Direct |
7,737
+28.17%
|
-
|
|
Jun 12
2024
|
Fred E Cohen |
BUY
Grant, award, or other acquisition
|
Direct |
7,737
+13.53%
|
-
|
|
Mar 04
2024
|
Eliana Clark EVP, Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
605
-0.84%
|
$19,360
$32.99 P/Share
|
|
Mar 04
2024
|
James Basta EVP, General Counsel |
SELL
Open market or private sale
|
Direct |
2,297
-2.74%
|
$73,504
$32.99 P/Share
|
|
Mar 01
2024
|
Glenn Goddard EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,628
+29.26%
|
-
|
|
Mar 01
2024
|
David Lebwohl EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,701
+29.37%
|
-
|
|
Mar 01
2024
|
John M Leonard President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
113,586
+10.58%
|
-
|
|
Mar 01
2024
|
Eliana Clark EVP, Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,230
+30.23%
|
-
|
|
Mar 01
2024
|
Derek Hicks EVP, Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
29,393
+30.69%
|
-
|
|
Mar 01
2024
|
James Basta EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
32,394
+27.86%
|
-
|
|
Mar 01
2024
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,966
+31.68%
|
-
|
|
Jan 08
2024
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,275
-2.49%
|
$65,975
$29.02 P/Share
|
|
Jan 03
2024
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,532
-10.69%
|
$160,428
$29.46 P/Share
|
|
Jan 03
2024
|
David Lebwohl EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,843
-9.7%
|
$169,447
$29.46 P/Share
|
|
Jan 03
2024
|
John M Leonard President and CEO |
SELL
Open market or private sale
|
Direct |
19,223
-2.22%
|
$557,467
$29.46 P/Share
|
|
Jan 03
2024
|
Eliana Clark EVP, Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
4,608
-5.1%
|
$133,632
$29.79 P/Share
|
|
Jan 03
2024
|
James Basta EVP, General Counsel |
SELL
Open market or private sale
|
Direct |
3,805
-6.88%
|
$110,345
$29.46 P/Share
|
|
Jan 03
2024
|
Derek Hicks EVP, Chief Business Officer |
SELL
Open market or private sale
|
Direct |
3,877
-9.49%
|
$112,433
$29.46 P/Share
|
|
Jan 03
2024
|
Glenn Goddard EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,365
-11.68%
|
$155,585
$29.46 P/Share
|
|
Jan 01
2024
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+6.34%
|
-
|
|
Jan 01
2024
|
John M Leonard President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,848
+0.9%
|
-
|
|
Jan 01
2024
|
David Lebwohl EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,187
+5.03%
|
-
|
|
Jan 01
2024
|
Glenn Goddard EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,062
+6.25%
|
-
|
|
Oct 31
2023
|
Muna Bhanji |
SELL
Open market or private sale
|
Direct |
265
-2.16%
|
$6,095
$23.9 P/Share
|
|
Jul 31
2023
|
Muna Bhanji |
SELL
Open market or private sale
|
Direct |
265
-2.12%
|
$11,130
$42.33 P/Share
|
|
Jul 06
2023
|
Muna Bhanji |
SELL
Open market or private sale
|
Direct |
1,867
-12.97%
|
$72,813
$39.3 P/Share
|
|
Jul 03
2023
|
Eliana Clark EVP, Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
360
-0.79%
|
$14,400
$40.51 P/Share
|
|
Jun 20
2023
|
Eliana Clark EVP, Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-9.97%
|
$225,000
$45.0 P/Share
|
|
Jun 20
2023
|
Eliana Clark EVP, Chief Technical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+9.07%
|
$60,000
$12.27 P/Share
|
|
Jun 14
2023
|
Frank Verwiel |
BUY
Grant, award, or other acquisition
|
Direct |
4,425
+27.41%
|
-
|
|
Jun 14
2023
|
William J Chase |
BUY
Grant, award, or other acquisition
|
Direct |
1,673
+8.11%
|
-
|
|
Jun 14
2023
|
Fred E Cohen |
BUY
Grant, award, or other acquisition
|
Direct |
4,425
+9.59%
|
-
|
|
Jun 14
2023
|
John F Crowley Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,425
+27.41%
|
-
|
|
Jun 14
2023
|
Jesse Goodman |
BUY
Grant, award, or other acquisition
|
Direct |
4,425
+27.41%
|
-
|
|
Jun 14
2023
|
Georgia Keresty |
BUY
Grant, award, or other acquisition
|
Direct |
4,425
+21.51%
|
-
|
|
Jun 14
2023
|
Muna Bhanji |
BUY
Grant, award, or other acquisition
|
Direct |
4,425
+23.51%
|
-
|
|
Apr 14
2023
|
William J Chase |
BUY
Grant, award, or other acquisition
|
Direct |
10,483
+37.75%
|
-
|
|
Mar 02
2023
|
James Basta EVP, General Counsel |
SELL
Open market or private sale
|
Direct |
1,088
-1.93%
|
$46,784
$43.88 P/Share
|
|
Mar 01
2023
|
Derek Hicks EVP, Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,558
+36.57%
|
-
|
|
Mar 01
2023
|
Glenn Goddard EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,484
+39.06%
|
-
|
|
Mar 01
2023
|
David Lebwohl EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,674
+35.24%
|
-
|